Abstract: Faldaprevir (FDV) is a potent, orally administered inhibitor of hepatitis C virus. In this single-centre, open-label, fixed-sequence, crossover study of 32 healthy adult male and female volunteers, subjects received either a single dose of cyclosporine (CsA) 50 mg (N = 16) or tacrolimus (TAC) 0.5 mg (N = 16), followed by a washout of at least 14 days. Each subject then received a loading dose of FDV 240 mg followed by 120 mg FDV once daily for 6 days. FDV 120 mg was then co-administered with an additional single dose of CsA (50 mg) or TAC (0.5 mg), followed by an additional 6 days of FDV 120 mg once daily. Intensive blood sampling was performed to assess the PK interaction potential. Assessment of relative BA indicated that exposure to CsA co-administered with FDV was similar to CsA alone. However, the AUC s,ss and C max,ss of FDV were increased by 23% and 41%, respectively, when FDV was co-administered with CsA. Exposure to TAC was slightly increased (AUC 0-∞ increased by 27%, no change in C max ) when TAC was co-administered with FDV. In contrast, exposure to FDV coadministered with TAC was similar to FDV alone. No unexpected safety findings arose from the trial. The limitations of the study (use of single, low dose of TAC and CsA, and only healthy volunteers in the trial) are discussed.
Recurrence of hepatitis C virus (HCV) infection after liver transplantation is a major source of morbidity and mortality. Overall, by the 5th-7th year post-transplantation, one-third of HCV-infected transplant recipients have developed allograft cirrhosis as a result of recurrence. The most significant factors determining disease progression are the use of organs from older donors, suboptimal immunosuppression and the presence of co-morbidities that affect the quality of the graft (e.g. biliary complications, metabolic syndrome). To reduce the potential for recurrence of infection, HCV antiviral treatment is generally required after liver transplantation [1] .
Faldaprevir is a second-generation protease inhibitor used for the treatment of hepatitis C virus infection, and it is currently being developed into an interferon-free regimen for the treatment of HCV infection [2, 3] . In vitro, FDV showed good potency against HCV genotypes (GT) 1, 4, 5 and 6 [4] . At a therapeutic dose of 120 mg once daily, when combined with pegylated interferon and ribavirin, FDV demonstrated high efficacy and good safety profiles in Phase II and III studies in HCV-infected patients and HCV-HIV coinfected patients [5] [6] [7] . Additionally, proof-of-clinical-concept studies have shown that FDV can be used in interferon-free regimens for the treatment of HCV infection with good efficacy and safety [8, 9] .
After oral administration of FDV soft gel capsules to HCVinfected patients, plasma attained peak FDV concentration at 3-6 hr after dosing [10] . Faldaprevir demonstrates nonlinear pharmacokinetics, with greater than dose-proportional increases in exposure over the dose range of 4-1200 mg in healthy volunteers [11] . In HCV-infected patients, when FDV dose was increased from 120 to 240 mg, exposure increased approximately five to seven times [12] (Boehringer Ingelheim data on file). Food has no clinically relevant effects on FDV absorption [13] . The mean elimination half-life of FDV in healthy volunteers and HCV-infected adult patients was approximately 20-30 hr [10, 11] ; therefore, FDV is given once daily in all treatment regimens for HCV infection.
At the therapeutic dose of 120 mg QD, FDV is an inhibitor of CYP2C9 [14, 15] and a weak inhibitor of CYP3A4, but has no effect on other CYPs [15] . In vitro data also suggest that FDV is a substrate of OATP1B1, a substrate and inhibitor of P-glycoprotein (P-gp) and an inhibitor of UDP-glucuronosyltransferase (UGT1A1) [14, 15] . Cyclosporine and TAC are calcineurin inhibitors used for the prevention of solid organtransplant rejection and have a narrow therapeutic range. Both immunosuppressants are substrates of cytochrome P450 3A (CYP3A) and P-glycoprotein (P-gp) transporters. Additionally, CsA is an inhibitor of several other transporter proteins, including OATP1B1, OATP1B3, BCRP and P-gp.
There currently exists an unmet medical need for treatments for recurrent hepatitis C infection following liver transplantation. SVR (sustained virologic response) rates in patients receiving PEG-IFNa and ribavirin after liver transplantation are low, with less than one-third of patients achieving SVR. Direct-acting antiviral agents (DAAs) have significantly increased the SVR rate, but the first generation of protease Author for correspondence: Fenglei Huang, Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Rd., Ridgefield, CT 06877, USA (e-mail fenglei.huang@boehringer-ingelheim.com).
inhibitors shows significant drug-drug interactions with CsA and TAC. For example, telaprevir increased total CsA and TAC exposure by 5.6 times and 70 times, respectively [16] , and boceprevir increased total CsA and TAC exposure by 2.7 times and 17 times, respectively [17] . For the second-generation NS3/4A protease inhibitor simeprevir, co-administration with CsA and TAC led to respective 5.7 times and 1.9 times increases in simeprevir AUC. It is thus not recommended for simeprevir to be given together with CsA [18] . Even for an all oral, interferon-free, three-drug combination containing protease inhibitors (ombitasvir, paritaprevir and ritonavir tablets; plus dasabuvir tablets; VIEKIRA PAK), CsA and TAC total exposure increased by 5.8 times and 57 times, respectively [19] . Use of elbasvir/grazoprevir, the newly licensed all oral, interferon-free, two-drug combination, which includes another second-generation protease inhibitor (grazoprevir), is not recommended for concurrent use with CsA or TAC, as this resulted in a 15-time increase in grazoprevir AUC and a twotime increase in elbasvir AUC [20] . In addition, all of these agents, with the exception of elbasvir/grazoprevir, must be given with food to maintain adequate systemic exposure [19, 21, 22] . However, food can decrease CsA [23] and TAC exposure [24] . All of these factors present a significant clinical challenge in the use of DAAs for the treatment of HCVinfected patients following liver transplantation [25] .
Given the unmet medical need for the treatment of HCV infection after liver transplantation and the likelihood that FDV can be given together with CsA or TAC, this study was conducted to investigate the pharmacokinetic interactions between steady-state FDV and single doses of CsA and TAC.
Materials and Methods
Subjects. Healthy adult male and female subjects aged 18-50 years (inclusive) with a body mass index of 18.5-29.9 kg/m 2 (inclusive) were eligible to be enrolled in the study. All subjects signed informed consent form before participation. Female volunteers were either postmenopausal or were using adequate contraceptive methods. Exclusion criteria comprised any findings in the medical examination that deviated from normal or any laboratory values outside the established reference range considered to be of clinical relevance by the investigator; any conditions, disorders or activities that could interfere with the pharmacokinetics of the study drugs; and current drug or alcohol abuse or tobacco smoking. For subjects that had used any drugs, nutraceuticals or herbal remedies that might influence study results, sufficient time was required for these substances to be eliminated before taking part in the study.
Study Design. This study was performed at Clinical Research Services Mannheim GmbH, Mannheim, Germany, in accordance with the International Conference on Harmonization guideline for Good Clinical Practice and the principles of the Declaration of Helsinki. The clinical trial protocol, the informed consent form and subject information were reviewed by the responsible local Independent Ethics Committee (Ethik-Kommission bei der Landes€ arztekammer Baden-W€ urttemberg, Stuttgart, Germany). The clinical trial application was also reviewed by the German Competent Authority (BfArM, Bonn, Germany).
In Group 1 (N = 16) ( All trial medications were administered with about 240 mL of water under supervision of the investigating physician or an authorized designee. On the PK profiling day, trial medications were administered after an overnight fast of at least 10 hr. On all other days, trial medication was administered 30 min. after a standard meal. (table 1) . At each time-point, 2.7 mL (for FDV) or 4 mL (for CsA and TAC) blood samples was collected into appropriately labelled blood collection tubes containing EDTA anticoagulant. Immediately after collection, each tube was inverted several times to distribute the anticoagulant. For FDV samples, centrifugation was carried out within 30 min. of blood sampling at 2000-4000 9 g for 10 min., and two aliquots of plasma were stored in individually labelled polypropylene tubes at À20°C for analysis. For CsA and TAC samples, two aliquots of whole blood were stored in individually labelled polypropylene tubes at À20°C for analysis.
Bioanalytical methods.
A validated high-pressure liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) method was used to quantify concentrations of FDV in EDTA plasma [16] . The calibration range was 10.0-10 000 ng/mL, the inter-assay accuracy (bias %) was 3.1-4.7%, and the inter-assay precision (CV %) was 3.3-5.7%.
Whole blood concentrations of CsA and TAC were determined by HPLC-MS/MS. The validated linear concentration range for CsA was 2.0-2000 ng/mL; the inter-assay accuracy (% bias) was 1.09-2.51%; and the inter-assay precision (CV %) was 3.22-9.73%. For TAC, the validated linear concentration range was 0.1-100 ng/mL, the interassay accuracy (% bias) was 0.554-5.19%, and the inter-assay precision (CV %) was 1.36-3.38%.
Safety assessments. Safety was assessed throughout the study using laboratory safety tests (serum biochemistry, haematology and urinalysis), 12-lead electrocardiograms, vital signs (blood pressure and pulse rate) and AE monitoring, and physical examinations. Therapeutic drug monitoring for CsA and TAC was performed 2 hr after dosing on Days -1 and 8, with further tests conducted at the discretion of the investigator.
Pharmacokinetic analysis. Pharmacokinetic analyses of CsA, TAC and FDV concentrations were conducted using non-compartmental methods in WinNonlin (Pharsight, Mountain View, CA, USA; version 5.2). The details of these methods have been described previously for single-dose pharmacokinetics [26] and steady-state pharmacokinetics [27] . Briefly, the area under the plasma concentration-time curve (AUC) was calculated using the trapezoidal rule, with the linear up/ log down algorithm. The elimination rate constant, k z (hr À1 ), was calculated by linear regression using the terminal log-linear portion of the plasma concentration-time curve. The elimination half-life (t 1/2 ) was estimated as ln 2/k z . Oral clearance (CL/F) was calculated as dose/AUC, and volume of distribution (V z /F) was calculated as CL/F/ k z . Univariate summary statistics were reported for all pharmacokinetic parameters.
Statistical analysis. The sample size of 32 (16 for each treatment arms) was determined using the method developed by Kupper and Hafner [28] on the basis of derived geometric intra-subject coefficient values of 21% and 32%, respectively, from the available data in the literature for CsA [23] and TAC [17] .
The effects of FDV on the relative bioavailability of CsA or TAC were determined by the pharmacokinetic parameters AUC 0-∞ , AUC 0-tz and C max . The effects of CsA or TAC on the relative bioavailability of FDV at steady-state were determined by the pharmacokinetic parameters AUC s,ss and C max,ss . The statistical model used to analyse relative bioavailability was an analysis of variance (ANOVA) model on a logarithmic scale. Point estimates of bioavailability, ratios of the adjusted by-treatment geometric means (gMeans), and two-sided 90% confidence intervals (CIs) were calculated.
Inferential statistical analysis (ANOVA) was not performed for other PK parameters such as t 1/2 , CL/F and V z /F. Instead, descriptive statistical analysis was performed and the geometric mean (gMean) and per cent geometric mean coefficient of variation (gCV %) were reported.
Results

Subjects.
A total of 32 subjects were entered into the trial (table 2) . In Group 1 (interaction of FDV and CsA), 16 subjects were enrolled and treated and 13 (81.3%) completed the study. Of the three subjects who did not complete the study, one subject was dropped by the investigator due to an adverse event (6.3%; mild anaemia, not considered by the investigator to be related to trial medication), and two subjects withdrew informed consent for personal reasons. In Group 2 (interaction of FDV and TAC), 16 subjects were entered and 15 were treated; one subject withdrew informed consent for personal reasons prior to dosing with trial medication. Of the 15 treated subjects, all completed the study.
Pharmacokinetic interaction between FDV and CsA. CsA exposure (AUC 0-∞ and AUC 0-tz ) was similar after coadministration of CsA and FDV when compared with CsA alone (table 3) . The inter-individual geometric coefficient of variation (gCV%) for AUC was between 16.2 and 25.2. C max was also similar between treatments. The median time to peak CsA concentration (t max ) was the same for both treatments (1.50 hr). gMean apparent clearance (CL/F), half-life (t 1/2 ) and mean residence time (MRT po ) of CsA were similar for both treatments (table 3) . Intra-individual comparisons of CsA AUC 0-∞ and C max demonstrated that CsA exposure was comparable between treatments ( fig. 1 ). The adjusted geometric mean ratios and 90% confidence intervals for AUC 0-∞ , AUC 0-tz and C max are shown in table 3.
FDV exposure (AUC s,ss , C max,ss , C 24,ss ) was somewhat increased after co-administration with CsA when compared with FDV alone (table 3) . The inter-individual variability of exposure parameters was high (gCV%, 196-331%), largely due to the very low exposure seen in one subject ( fig. 2) . The time to peak FDV concentration (t max,ss ) at steady-state was somewhat shorter after co-administration with CsA compared to FDV administered alone. The gMean CL/F ,ss was similar between treatments (table 3) . Intra-individual and gMean comparisons of FDV AUC s,ss , C max,ss and C 24,ss demonstrated that exposure to FDV was, in general, slightly increased after co-administration with CsA when compared with FDV alone (fig. 2) .
Pharmacokinetic interaction between FDV and TAC. TAC exposure (AUC 0-∞ and AUC 0-tz ) was somewhat higher after co-administration of TAC and FDV when compared with TAC alone (table 4) . The inter-individual gCV% for the AUC parameters was between 57.6 and 66.2. However, C max was similar between treatments. The time to peak TAC concentration (t max ) was slightly longer for TAC co-administered with FDV than for TAC alone (median, 3.00 hr versus 1.50 hr). The geometric mean CL/F was somewhat lower for TAC + FDV than for TAC alone, and MRT po and t 1/2 were somewhat longer (table 4) . Intra-individual comparisons of AUC 0-∞ demonstrated that exposure to TAC was generally higher after co-administration with FDV than after administration of TAC alone ( fig. 3 ). This increase was not observed for C max ( fig. 3) .
FDV exposure (AUC s,ss and C max,ss ) was similar after coadministration with TAC when compared to FDV alone (table 4). The inter-individual variability (gCV%) of the exposure parameters ranged from 35.7-56.1% (table 4). The time to peak FDV concentration (t max,ss ) at steady-state was the same for both treatments (median, 3.0 hr), but the range of values was increased for FDV + TAC (2.00-12.00 hr) compared with FDV alone (1.50-6.00 hr). The gMean CL/F ,ss was similar between treatments (table 4). Intra-individual and gMean comparisons of FDV AUC s,ss , C max,ss and C 24,ss demonstrated that exposure to FDV was similar after co-administration with TAC when compared with administration of FDV alone (fig. 4) .
Safety.
The frequency of adverse events is summarized in Table S1 .
During trial periods in which FDV was administered, AEs were similar to those reported in previous trials of healthy volunteers; with GI events the most frequently reported AEs (especially nausea and diarrhoea). Laboratory assessments demonstrated transient, clinically irrelevant bilirubin increases (primarily indirect bilirubin) similar to those observed in previous trials with FDV and most likely attributable to inhibition of UGT1A1 by FDV. There were no other notable changes in laboratory parameters or vital signs.
Discussion
In HCV-infected patients who have received a liver transplant, viral infection often recurs and requires treatment [29] . The current trial was designed to investigate potential drug-drug interactions between FDV and the immunosuppressants CsA and TAC.
Due to the long half-life of FDV, a fixed-sequence design was considered optimal. The fixed-sequence design was not expected to lead to systematic errors in the estimation of treatment effects, as the trial duration was short enough so that non-specific time-dependent effects were not expected. The doses of CsA and TAC selected for this study were optimal for investigating potential drug-drug interactions without jeopardizing subject safety. The doses of TAC and CsA were at the lower end of the standard therapeutic dosing or were subtherapeutic doses to ensure an adequate margin of safety if a marked increase in immunosuppressant concentration occurred with FDV co-administration [23, 24] . Additionally, as potential toxicity may occur after chronic treatment of healthy volunteers with CsA or TAC [23, 24, 30] , it was reasonable to administer these immunosuppressants as single doses in the study. The safety profile of FDV in healthy volunteers allowed dosing to steady-state, and therefore, multiple dosing regimens at the therapeutic dose of 120 mg [2, 3] were selected in this drug-drug interaction study to mimic the chronic treatment of HCV infection with FDV [31] . The typical cyclosporine dose for organ-transplant patients is 3-15 mg/kg divided into a twice-daily dose [23] ; the typical tacrolimus dose for organtransplant patients is 0.075-0.2 mg/kg/day (twice-daily dose) [24] . The selection of low to subtherapeutic doses in this study is not optimal for uncovering possible effects of CsA and TAC on the PK of FDV. This limitation, along with other limitations of the study, will be comprehensively discussed in the later sections of this manuscript. Following co-administration of CsA with steady-state FDV, CsA exposure was unchanged (table 3) . As expected, inhibition of CYP3A and P-gp by FDV 120 mg QD [15] did not appreciably affect the metabolism of CsA. The concomitant administration of steady-state FDV 120 mg with TAC led to a slight elevation in total TAC exposure, but not peak exposure (table 4) . These results are consistent with TAC being a sensitive CYP3A4 and P-gp substrate and FDV being a weak inhibitor of CYP3A and P-gp.
In the presence of CsA, steady-state FDV exposure was slightly increased (AUC s,ss , 23%, C max,ss , 41%, C 24,ss 17%; table 3). With a C max,ss value of 164 ng/mL (approximately 0.13 lM), a 50 mg dose of CsA, and the Ki values for OATP1B1 (0.014 lM), CYP3A4 (1-5 lM) and P-gp (7.24 lM) [32] , using the formula proposed in the FDA drugdrug interaction guidance for predicting in vivo drug-drug interaction [31] , the calculated R-value was approximately 2 for systemic OATP1B1, 35-168 for intestinal CYP3A4 and 25 for intestinal P-gp. The data suggest that adequate inhibition of these enzyme/transporters was achieved at the dose used in this study. Given that the increase in FDV C max,ss (41%) was higher than for AUC s,ss (23%), it is suggested that the slight increase in exposure was primarily due to pre-systemic inhibition of intestinal CPY3A4 or P-gp. This may also indicate that inhibition by OATP1B1 contributed minimally to the increase in FDV exposure in the present study. For comparison, using the same FDA formula, an R-value of approximately 3 was estimated for pitavastatin, a sensitive and relatively specific OATP1B1 substrate (an index OATP1B1 substrate cited by FDA) [31] ; the exposure of pitavastatin was increased by 4.5 times when co-administered with CsA in vivo [33] . In the FDV clinical development programme, FDV exposure was increased approximately two times when co-administered with itraconazole, a strong CYP3A inhibitor and an inhibitor P-gp [34] . However, when co-administered with atazanavir/ritonavir (300/100 mg), a moderate to strong inhibitor of CYP3A [31, 35] and an inhibitor of OATP1B1 and P-gp [31, 36, 37] , the exposure was increased by approximately 1.8 times [38] . This increase appeared to be numerically explainable by the inhibition of CYP3A and P-gp alone. The exact mechanism underlying the aforementioned clinical observations remains unclear at this point, but a potential explanation for the apparently insignificant contribution of OATP1B1 inhibition to the FDV exposure increase may be related to the limited fractional contribution of OATP1B1-mediated hepatic uptake to the overall FDV disposition (clearance) or Fe [39] , as well as the complex interplay of metabolizing enzymes (CYP3A4) and transporters (OATP1B1) [40] of FDV [41] . In vitro data have suggested that OATP1B1-mediated hepatic uptake only contributed to approximately 45% of FDV hepatic update [42] . It is possible that it may contribute even less to overall FDV disposition in vivo, as metabolism contributes a significant portion of the total clearance of FDV [43] ; in contrast, OTAP1B1-mediated hepatic uptake contributed 70% of the overall disposition of pitavastatin (OATP1B1 contributed to 90% of the pitavastatin hepatic active uptake) [40] . Fe has been shown to be an important factor determining the magnitude of DDIs [39, 40] . Finally, FDV exposure was unchanged when co-administered with TAC, suggesting that at the studied dose, TAC has no effect on FDV metabolism by CYP3A and transport by P-gp.
To ensure the safety of the healthy volunteers enrolled in this study, CsA and TAC were administered as single doses at the lower end of the therapeutic range or subtherapeutic dose [23, 24] . Although this represents a limitation of the study, evaluation of drug-drug interactions using subtherapeutic doses or micro-doses has been proven to be a valid approach in evaluating a drug as a substrate (victim) of cytochrome-P450 or transporter-mediated inhibition [44, 45] ; it has also been recognized as a valid method by the FDA [31] . In fact, low or subtherapeutic single doses of CsA and TAC have been used to evaluate the effects of telaprevir [16] , boceprevir [17] , simeprevir [46] and ombitasvir/paritaprevir/dasabuvir/r [19] on the pharmacokinetics of CsA and TAC, and these data have been used in the FDA-approved prescribing information. The potential effects of FDV on CsA and TAC are thus believed to have been adequately evaluated, although the effects of these immunosuppressants on the pharmacokinetics of FDV were not fully evaluated in the current study.
CsA and TAC are both inhibitors of CYP3A and P-gp, and CsA additionally inhibits OATP1B1. As previously discussed, intestinal P-gp and CYP3A4 and systemic OATP1B1 inhibition of FDV by CsA has been adequately evaluated. As CsA is a weak inhibitor of CYP3A [31, 47] , the effect of CsA on systemic CYP3A activity is expected to be limited. The effect of CsA on the systemic clearance of digoxin (a specific substrate of P-gp) was reported to be negligible based on a larger crossover, controlled clinical study [48] and was reported as limited in a case report of two patients [49] . Based on the data from this study, together with the clinical and in vitro data from FDV clinical development programme and the published data on CsA's inhibition of CYP3A and P-gp, it is reasonable to expect the effect of CsA on FDV exposure to be limited. For TAC, which is, at most, a very weak in vivo inhibitor of CYP3A and P-gp [50, 51] , a minimal increase in FDV exposure is expected if the highest therapeutic dose of TAC and a therapeutic dose of FDV is to be given together.
In the FDV clinical development programmes, FDV exposure was increased by five times (based on trough concentration) [12] and seven times (based on AUC 0-24,ss , Boehringer Ingelheim data on file) when FDV dose was increased from 120 mg to 240 mg, but the safety profiles were similar for both doses [5, 52] . Given the wide safety margin of FDV (five to seven times from therapeutic exposure), the potential effects of CsA or TAC on the pharmacokinetics of FDV would not be of clinical importance. FDV is an in vitro inhibitor of CYP 2C8 with a Ki value of 4.66 lM. Using the FDA net effect model [31] , with a therapeutic dose of 120 mg FDV, the projected increase in AUC for a sensitive CYP 2C8 substrate by FDV inhibition is <1.3 times (Boehringer Ingelheim data on file). Additionally, both FDV and CsA are weak inhibitors of CYP 3A4 [31, 53] . Thus, it is reasonable to assume that the concomitant use of FDV and CsA with drugs that are substrates of both CYP2C8 and CYP3A4 (e.g. repaglinide, loperamide) may increase the AUC more than CsA or FDV is given with these substrates alone [54, 55] .
Another limitation of this study is that it was conducted on healthy volunteers, as opposed to in a liver transplant patient population. In general, drug-drug interaction results obtained from a healthy volunteer study can be extrapolated to a patient population [31] . In fact, the drug-drug interaction (DDI) studies for the direct-acting antivirals currently licensed for the treatment of HCV with immunosuppressants were all conducted with healthy volunteers, and results of these DDIs were included in the FDA-approved prescribing information [18, [20] [21] [22] 56, 57] . It has, however, been reported that HCV infection may lead to a reduction in the dose of CsA or TAC required to achieve a given blood level, likely due to the down-regulation of hepatic CYP3A4, impaired function of hepatic P-gp, or both [58] ; this effect may be reversed when the HCV-associated inflammatory response is eliminated by antiviral therapy. In addition, liver function may be improved with time after transplantation [59] . Given that both CsA and TAC are drugs with narrow therapeutic ranges [23, 24] , caution should be taken when extrapolating the results of this study to treatment of HCV infection in postliver transplant recipients [18, [20] [21] [22] 56, 57] . No unexpected safety findings arose during this trial. During trial periods in which FDV was administered, GI events were the most frequent AEs, and transient, clinically irrelevant bilirubin increases (primarily in indirect bilirubin) also were observed [60] , both of which are consistent with previous trials with healthy volunteers [61] . The types and frequencies of AEs for FDV co-administration with CsA or TAC did not appear to be substantially different from those reported for FDV alone.
In summary, despite a slight increase in FDV exposure (22% based on AUC s,ss for interaction with CsA only) and TAC (27% based on AUC 0-∞ ), co-administration of FDV 120 mg QD at steady-state with single doses of CsA 50 mg and TAC 0.5 mg did not lead to clinically relevant alterations in exposure to CsA, TAC or FDV. The limitations of the current study were that the interactions between FDV and CsA and TAC were evaluated in healthy volunteers and single and low doses of CsA and TAC were used.
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